| NCT06260514 | Study of APR-1051 in Patients With Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-06-13 | 2028-06 | 2027-06 |
| NCT04905914 | Study Of ATRN-119 In Patients With Advanced Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2023-01-09 | 2028-02 | 2028-02 |
| NCT04638309 | APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) | TERMINATED | PHASE1 | 2021-09-20 | 2022-04-25 | 2022-04-25 |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | TERMINATED | PHASE1, PHASE2 | 2021-03-02 | 2021-08-24 | 2021-08-23 |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | COMPLETED | PHASE1, PHASE2 | 2020-06-25 | 2022-04-30 | 2022-04-30 |
| NCT04214860 | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies | COMPLETED | PHASE1 | 2019-12-13 | 2022-01-14 | 2022-01-14 |
| NCT03931291 | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant | COMPLETED | PHASE2 | 2019-09-16 | 2022-01-14 | 2021-08-27 |
| NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | COMPLETED | PHASE3 | 2019-01-11 | 2022-01-14 | 2020-11-27 |
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma | TERMINATED | PHASE1, PHASE2 | 2018-01-18 | 2018-08-08 | 2018-08-08 |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | COMPLETED | PHASE2 | 2017-07-31 | 2019-07-10 | 2019-07-10 |
| NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | COMPLETED | PHASE1, PHASE2 | 2014-03 | 2019-04 | 2019-04 |
| NCT00900614 | Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer | COMPLETED | PHASE1 | 2009-05 | 2010-10 | 2010-10 |